RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Patient experiences and preferences for specific on-demand treatments for Parkinson's Disease-related “OFF” episodes (G10)
Thach, A., Sutphin, J. N., Coulter, J. R., & Mansfield, C. A. (2020). Patient experiences and preferences for specific on-demand treatments for Parkinson's Disease-related “OFF” episodes (G10). Journal of Managed Care Pharmacy, 26(4-a Suppl), S40. https://doi.org/10.18553/jmcp.2020.26.4-a.s1
BACKGROUND: Patients with Parkinson’s disease (PD) develop
potentially disabling “OFF” episodes—periods when symptoms worsen or reemerge—that
may be treated with on-demand therapies. OBJECTIVE: We evaluated patient
treatment experiences with PD “OFF” episodes and preferences for on-demand
treatment approaches. METHODS: US adults (18-75 years [y]) with a self-reported
physician diagnosis of PD for ≥5 y or <5 y with “OFF” episodes on levodopa were
recruited via online panels, physician referrals, online support groups, and
targeted advertising to participate in an online survey. The survey gave
instructions for use of hypothetical on-demand “OFF” episode treatments
administered via injection, inhalation, and dissolvable sublingual film and
asked participants about treatment preferences. It also asked about their
experience with currently available on-demand treatments (apomorphine
hydrochloride injection [Apokyn] and inhaled levodopa powder [Inbrija]). RESULTS:
Among the 300 participants, 60% were male with a mean age of 59 y. Most
participants (98%) experienced “OFF” episodes, with 50% having ≥1 episode/day
and 90% having ≥1 episode/week. Among participants who had ever taken
apomorphine hydrochloride injection (n=54) or inhaled levodopa powder (n=54),
57% and 59%, respectively, were currently taking those medications. When “OFF” episodes
occur, participants most commonly reported waiting until symptoms dissipate or
until their next dose of maintenance medication (53%). They also reported
taking their next, partial, or extra dose of maintenance medication, calling
their doctor, or taking an “OFF” episode medication. When presented with
hypothetical on-demand “OFF” episode treatments, 76% of participants rated a
dissolvable sublingual film as “easy” or “very easy” to potentially administer
without assistance, compared with administration by injection (28%) or inhalation
(59%). Of 298 participants with at least some interest in ondemand “OFF”
episode treatment, preference ranking for medication administration was
dissolvable sublingual film with potential mouth/ lip sores (47%), inhaled
medicine with potential cough or mild respiratory infection (31%), and
injection with potential site reactions (18%). CONCLUSIONS: More than half of
participants with on-demand treatment experience for PD-related “OFF” episodes
were currently using those treatments. For hypothetical on-demand treatment, a dissolvable
sublingual film was rated as the easiest potential route of administration
without assistance and, despite potential side effects, was preferred over
injection or inhalation. SPONSORSHIP: Sunovion Pharmaceuticals